Buy Compazine (Prochlorperazine 5mg) Online - Phenothiazine Dopamine D2 Antagonist for Severe Nausea Vomiting Vertigo

Generic Compazine (Prochlorperazine 5 mg) Medication guide:

💊 Introduction to Compazine

Compazine is a prescription oral medication containing prochlorperazine maleate as its active ingredient. Prochlorperazine was developed by SmithKline & French Laboratories (later part of SmithKline Beecham, then GlaxoSmithKline) and received FDA approval in the United States in 1956. It represents one of the first-generation phenothiazine medications developed shortly after chlorpromazine (the original phenothiazine antipsychotic) and became the antiemetic prochlorperazine standard through decades of clinical use.

The medication has a distinctive history in modern medicine. The original Compazine brand was discontinued in the United States in 2001 by GlaxoSmithKline but generic prochlorperazine remains widely available worldwide as the standard treatment for severe nausea and vomiting. The generic prochlorperazine sold under the Compazine brand name on rxshop.md is manufactured by Abbott India under WHO-GMP quality standards. Available as 5 mg oral tablets — the standard antiemetic dose. In broader use, prochlorperazine is also available as 10 mg and 25 mg tablets, 25 mg rectal suppositories, and injectable solutions for hospital use.

Prochlorperazine holds a unique position in the antiemetic pharmacopeia. While newer 5-HT3 receptor antagonists (ondansetron, granisetron) have become first-line therapy for chemotherapy-induced nausea and vomiting, prochlorperazine remains critically important for several reasons. First, it works through a different mechanism (dopamine D2 antagonism) than 5-HT3 blockers, making it effective when 5-HT3 antagonists fail or when combination therapy is needed for refractory nausea. Second, it provides additional multi-receptor coverage (H1, muscarinic, alpha-1 blockade) that addresses various nausea etiologies including vestibular disorders and migraine-associated nausea. Third, it offers substantially lower cost than newer antiemetics, making it accessible in cost-sensitive healthcare settings worldwide.

🔬 Understanding Nausea and Vomiting Physiology

Understanding the neural pathways that mediate nausea and vomiting is essential for optimal antiemetic therapy selection. The vomiting reflex is one of the most complex protective mechanisms in the body, involving multiple neurotransmitters and brain regions.

The Vomiting Center

The vomiting center is located in the lateral reticular formation of the medulla oblongata and coordinates the motor pattern of vomiting. It receives inputs from four distinct pathways:

Neurotransmitters Involved

Dopamine (D2 receptors)

D2 receptors are abundant in the chemoreceptor trigger zone and are the primary target of prochlorperazine, metoclopramide, and haloperidol. Blocking D2 receptors at CTZ effectively prevents nausea signaling from various chemical stimuli.

Serotonin (5-HT3 receptors)

5-HT3 receptors are found in the gut and CTZ. Chemotherapy causes serotonin release from GI enterochromaffin cells, activating 5-HT3 receptors and triggering vomiting. Ondansetron and granisetron selectively block these receptors.

Histamine (H1 receptors)

H1 receptors mediate motion sickness and vestibular-related nausea. Prochlorperazine blocks H1 receptors providing vestibular symptom control, as do dedicated antihistamines like meclizine.

Acetylcholine (Muscarinic receptors)

Muscarinic M1 receptors in the vestibular apparatus mediate motion-related nausea. Prochlorperazine blocks muscarinic receptors providing additional anti-motion sickness effect (similar to scopolamine).

Substance P (NK1 receptors)

Neurokinin-1 receptors mediate delayed chemotherapy nausea. Newer NK1 antagonists (aprepitant) block these receptors for delayed emesis prevention.

🧬 Chemistry and Pharmacology of Prochlorperazine

Prochlorperazine has the chemical formula C₂₀H₂₄ClN₃S (base) with molecular weight approximately 373.9 g/mol. In pharmaceutical formulations, prochlorperazine is available as several salts:

• Prochlorperazine maleate: Standard oral tablet form (Compazine tablets, Stemetil)
• Prochlorperazine edisylate: Injectable solution and syrup form
• Prochlorperazine mesylate: Used in some non-US markets

Structurally, prochlorperazine is a piperazine-substituted phenothiazine — the same tricyclic phenothiazine backbone as chlorpromazine (the original first-generation antipsychotic) but with a piperazine ring in the side chain that confers enhanced antiemetic potency and reduced antipsychotic sedation compared to chlorpromazine. This selectivity makes prochlorperazine particularly suited to antiemetic use.

Mechanism of Action

Prochlorperazine works through multi-receptor antagonism at several central and peripheral receptor sites, producing a broad spectrum of clinical effects:

Pharmacokinetic Profile

Metabolism and Elimination

Prochlorperazine undergoes extensive hepatic metabolism primarily through cytochrome P450 2D6 (CYP2D6). This has several important clinical implications: CYP2D6 genetic polymorphism affects clearance — poor metabolizers may have higher blood levels and increased side effects, while ultra-rapid metabolizers may have reduced antiemetic effectiveness. Common CYP2D6 inhibitor drug interactions include SSRIs (fluoxetine, paroxetine), quinidine, and terbinafine. Additionally, prochlorperazine metabolites retain some pharmacological activity contributing to the overall clinical effect and duration.

🎯 Indications and Patient Selection

Compazine has multiple FDA-approved indications reflecting its multi-receptor pharmacology:

Antiemetic Indications

• Severe nausea and vomiting — the primary current use of prochlorperazine
• Chemotherapy-induced nausea and vomiting — as second-line therapy or combination with 5-HT3 antagonists
• Post-surgical nausea and vomiting (PONV) — prevention and treatment after anesthesia
• Radiation-induced nausea — for cancer patients undergoing radiotherapy
• Vertigo — vestibular disorders including Ménière disease and vestibular neuritis
• Severe gastroenteritis vomiting — when supportive care alone is insufficient

Psychiatric Indications

• Schizophrenia — as first-generation antipsychotic (though newer atypical antipsychotics preferred)
• Acute psychotic episodes — for rapid symptom control
• Short-term non-psychotic anxiety — occasionally used for severe anxiety

Off-Label Uses

• Severe migraine with nausea: Highly effective for migraine-associated nausea
• Motion sickness: Alternative when other antihistamines fail
• Hiccups (intractable): Occasional use for persistent hiccups
• Hyperemesis gravidarum: Historically used, though other agents preferred in pregnancy

Ideal Patient Selection

🚫 Contraindications

💉 Dosage and Administration

Antiemetic Dosing

Psychiatric Dosing

For psychiatric indications, doses are substantially higher and titrated based on response:

• Schizophrenia: Starting 5-10 mg TID-QID, titrated up to 100-150 mg/day divided
• Non-psychotic anxiety: 5 mg TID-QID, maximum 20 mg/day for maximum 12 weeks
• Elderly patients: Reduce doses by 25-50 percent given increased side effect sensitivity

Administration Rules

• Take with full glass of water at consistent times
• Can be taken with or without food
• Do not crush or split tablets (may irritate mucosa)
• Use lowest effective dose for shortest duration for antiemetic use
• Avoid concurrent alcohol — additive CNS depression
• Rise slowly from lying or sitting to prevent orthostatic hypotension

⚠️ Serious Warnings

FDA Black Box Warning - Elderly with Dementia

Extrapyramidal Symptoms (EPS)

Prochlorperazine causes extrapyramidal symptoms in a substantial proportion of patients through D2 antagonism in the nigrostriatal pathway. Types of EPS include:

• Acute dystonia: Painful sustained muscle contractions (torticollis, oculogyric crisis, laryngospasm) — typically within first days of therapy, more common in young males
• Akathisia: Motor restlessness and inability to sit still — very distressing for patients
• Parkinsonism: Tremor, rigidity, bradykinesia mimicking Parkinson disease
• Tardive dyskinesia: Late-onset involuntary movements (tongue, face, extremities) — potentially irreversible with long-term use

EPS treatment includes: dose reduction, anticholinergic medications (benztropine, trihexyphenidyl) for acute dystonia and parkinsonism, benzodiazepines or propranolol for akathisia, and immediate discontinuation if tardive dyskinesia develops.

Neuroleptic Malignant Syndrome (NMS)

📊 Clinical Effectiveness Data

Prochlorperazine has been extensively studied over more than six decades. Typical clinical response metrics:

⚠️ Side Effect Profile

Common Side Effects

Most prochlorperazine side effects are dose-dependent and relate to its multi-receptor profile:

• Drowsiness and sedation: Very common — expected effect
• Dry mouth (xerostomia): Common — muscarinic effect
• Blurred vision: Common — muscarinic effect
• Constipation: Common — muscarinic effect
• Orthostatic hypotension: Common — alpha-1 blockade
• Dizziness on standing: Common — orthostatic effect
• Restlessness (akathisia): Moderately common — EPS
• Muscle stiffness: Moderately common — EPS
• Tremor: Moderately common — EPS
• Weight gain: Long-term use
• Menstrual irregularities: Long-term use — hyperprolactinemia
• Sexual dysfunction: Long-term use — hyperprolactinemia

Serious Side Effects

🔄 Drug Interactions

Major Interactions

🛡️ Special Populations

Elderly Patients Over 65

Increased sensitivity to sedation, hypotension, EPS, and cognitive effects. FDA Black Box warning about increased mortality in dementia patients. Start at 25-50 percent reduced doses and titrate very slowly. Monitor cognitive status and fall risk carefully.

Pediatric Population

Contraindicated in children under 2 years or under 20 pounds. Not for pediatric surgery use due to severe EPS risk. Weight-based dosing for older children with careful monitoring for dystonia and other EPS. Metoclopramide often preferred alternative.

Hepatic Impairment

Extensive hepatic metabolism means impaired liver function significantly affects clearance. Reduce doses and monitor for accumulation. Contraindicated in severe hepatic impairment given hepatotoxicity risk.

Renal Impairment

Mild-moderate renal impairment does not require dose adjustment. Severe renal impairment may require monitoring given some renal elimination of metabolites.

Pregnancy and Lactation

Pregnancy Category C — animal studies show reproductive toxicity, use only if benefit justifies risk. Third trimester exposure risks neonatal EPS and withdrawal symptoms. Excreted in breast milk — avoid or discontinue breastfeeding during use.

Parkinson Disease Patients

Prochlorperazine worsens Parkinson symptoms through D2 antagonism. Generally avoided in this population. Alternative antiemetics like ondansetron preferred.

🔬 Comparison with Other Antiemetics

🔗 Combination Therapy Considerations

📆 Long-Term Use Considerations

While prochlorperazine is typically used short-term for acute nausea episodes, some patients require longer-term use for chronic vestibular disorders or psychiatric indications. Long-term considerations include:

• Tardive dyskinesia monitoring — Assess every 3-6 months during long-term therapy
• Metabolic monitoring — Weight, glucose, lipids as with other antipsychotics
• QT interval assessment — Baseline and periodic ECG for high-dose or high-risk patients
• Prolactin levels — If sexual dysfunction, menstrual changes, or galactorrhea develop
• Cognitive assessment — Particularly in elderly for confusion or dementia symptoms
• Bone density — Long-term prolactin elevation can affect bone health
• Regular re-evaluation of continued need — Try dose reduction or discontinuation trials

📦 Storage and Handling

👨‍⚕️ When to Contact Your Doctor

• Signs of NMS: high fever, severe muscle rigidity, confusion
• Acute dystonic reactions: painful sustained muscle contractions
• New involuntary movements suggesting tardive dyskinesia
• Severe akathisia or motor restlessness
• Fainting or severe dizziness on standing
• Palpitations or fainting suggesting arrhythmia
• Signs of allergic reaction: rash, swelling, difficulty breathing
• Unexplained fever, sore throat, unusual bleeding suggesting blood dyscrasia
• Yellowing of skin or eyes suggesting liver injury
• New or worsening seizure activity
• Persistent nausea despite therapy or worsening symptoms
• Starting new medications especially other CNS depressants or QT-prolonging drugs
• Pregnancy planning or confirmed pregnancy
• Sexual dysfunction, menstrual changes, or breast discharge

🌟 Key Takeaways

See all Compazine questions (32)